TAAR1 agonist ulotaront delays gastric emptying of solids in patients with schizophrenia and concurrent metabolic syndrome with prediabetes
Authors' conclusion
Ulotaront delayed the GE of solids in patients with schizophrenia and concurrent MetS with prediabetes. Additional studies are needed to assess whether treatment with TAAR1 agonists is associated with weight loss and glucoregulatory improvement.
Study context
- Population
- Patients with schizophrenia and concurrent metabolic syndrome (MetS) (≥3 of 5 criteria) with prediabetes (HbA1c 5.7–6.4% and/or fasting HOMA-IR ≥2.22)27 completed
- Participants
- 31 patients
- Comparison
- Ulotaront 150 mg vs previous antipsychotic
- Primary endpoint
- GE of solids half-time (T1/2) by scintigraphy
Methodological detailsopen-label, two-sequence, single oral dose
- Open-label
- Two-sequence
- Single oral dose
Primary result
As reported in the abstract
GE of solids T1/2
P = 0.006
Further findings
Gastric retention · 1 h post-meal
P = 0.015
Gastric retention · 2 h post-meal
P = 0.023
Gastric retention · 4 h post-meal
P = 0.002
Original publication
TAAR1 agonist ulotaront delays gastric emptying of solids in patients with schizophrenia and concurrent metabolic syndrome with prediabetes. Diabetes Obes Metab. Published 27 March 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →